PCMP-E53 Antibody
Description
Antibody Structure and Epitope Recognition
E53 engages the fusion loop of the flavivirus envelope (E) glycoprotein, a conserved region critical for viral entry. Key structural insights include:
-
Binding Interface: E53 interacts with 12 residues across the fusion loop (G104, C105, G106, L107, G109, K110) and the adjacent bc loop (C74, P75, T76, M77, G78, E79) of WNV E protein .
-
Cryo-EM Analysis: Preferential binding to immature virions due to epitope inaccessibility in mature virions .
-
Low Shape Complementarity: The antibody-antigen interface has a shape complementarity score of S c=0.49, indicating a loose fit .
Mechanism of Action
E53 exhibits dual activity: neutralization and antibody-dependent enhancement (ADE) depending on viral maturation status and target cell type:
Key Findings:
-
E53 increases infectivity of immature WNV by >1,000-fold in FcγR-expressing cells at sub-neutralizing concentrations .
-
Neutralization requires binding to hybrid mature/immature particles, preventing pH-dependent conformational changes .
In Vivo Efficacy and Limitations
Studies in murine models reveal dose-dependent protection and Fc-mediated effector functions:
Table 1: Survival Rates in WNV-Infected Mice Treated with E53
| Mouse Genotype | E53 Dose (μg) | Survival Rate | Mechanism |
|---|---|---|---|
| Wild-type | 400 | 90% | FcγR and C1q-dependent neutralization |
| FcγR −/− | 400 | 67% | Partial loss of protection |
| C1q −/− × FcγR −/− | 400 | 0% | Complete loss of protection |
Critical Insight: E53’s protective efficacy relies on complement (C1q) and Fcγ receptors, as shown in knockout models .
Therapeutic Implications
-
Vaccine Design: Fusion-loop antibodies like E53 pose challenges due to ADE risk but inform epitope-engineering strategies (e.g., in silico scFv variants) .
-
Neutralization Threshold: E53 requires high stoichiometry for neutralization, which mature virions evade due to epitope occlusion .
-
Cross-Reactivity: E53 binds DENV and WNV but shows weaker neutralization against DENV due to residue M77→Q substitution .
Key Research Gaps
-
Role of partially immature particles in human pathogenesis.
-
Strategies to eliminate ADE while retaining cross-reactive neutralization.
